Bunaciu, R. P., MacDonald, R. J., Jensen, H. A., Gao, F., Wang, X., Johnson, L., . . . Yen, A. (2018). Retinoic acid and 6-formylindolo(3,2–b)carbazole (FICZ) combination therapy reveals putative targets for enhancing response in non-APL AML. Leuk Lymphoma.
Citación estilo ChicagoBunaciu, Rodica P., Robert J. MacDonald, Holly A. Jensen, Feng Gao, Xin Wang, Lynn Johnson, Jeffrey D. Varner, and Andrew Yen. "Retinoic Acid and 6-formylindolo(3,2–b)carbazole (FICZ) Combination Therapy Reveals Putative Targets for Enhancing Response in Non-APL AML." Leuk Lymphoma 2018.
Cita MLABunaciu, Rodica P., et al. "Retinoic Acid and 6-formylindolo(3,2–b)carbazole (FICZ) Combination Therapy Reveals Putative Targets for Enhancing Response in Non-APL AML." Leuk Lymphoma 2018.